INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) was the target of some unusual options trading on Friday. Stock investors purchased 3,375 put options on the stock. This represents an increase of 101% compared to the typical volume of 1,681 put options.
Institutional Investors Weigh In On INmune Bio
Several institutional investors have recently bought and sold shares of INMB. Rhumbline Advisers lifted its stake in INmune Bio by 16.9% in the 4th quarter. Rhumbline Advisers now owns 16,744 shares of the company's stock valued at $78,000 after acquiring an additional 2,424 shares in the last quarter. Raymond James Financial Inc. bought a new stake in INmune Bio in the 4th quarter valued at approximately $2,221,000. LPL Financial LLC raised its stake in shares of INmune Bio by 33.0% during the 4th quarter. LPL Financial LLC now owns 19,072 shares of the company's stock worth $89,000 after purchasing an additional 4,730 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company's stock worth $53,000 after purchasing an additional 5,461 shares in the last quarter. Finally, Diametric Capital LP raised its stake in shares of INmune Bio by 24.6% during the 4th quarter. Diametric Capital LP now owns 36,699 shares of the company's stock worth $171,000 after purchasing an additional 7,244 shares in the last quarter. Institutional investors own 12.72% of the company's stock.
INmune Bio Stock Performance
NASDAQ INMB traded down $0.16 during trading on Monday, hitting $6.22. The stock had a trading volume of 2,098,448 shares, compared to its average volume of 312,116. The company has a market capitalization of $142.94 million, a PE ratio of -3.22 and a beta of 1.55. The company's 50-day moving average price is $7.50 and its two-hundred day moving average price is $7.32. INmune Bio has a 12 month low of $4.32 and a 12 month high of $10.50.
INmune Bio (NASDAQ:INMB - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.43) EPS for the quarter, meeting the consensus estimate of ($0.43). The firm had revenue of $0.05 million during the quarter. As a group, equities analysts anticipate that INmune Bio will post -2.24 earnings per share for the current fiscal year.
About INmune Bio
(
Get Free Report)
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Read More
Before you consider INmune Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and INmune Bio wasn't on the list.
While INmune Bio currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
